Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins

Journal of Infectious Diseases

Volumn 202, Issue 6, 2010, Pages 862-866

  Ray, Ranjit ^a   Meyer, Keith ^a   Banerjee, Arup ^a   Basu, Arnab ^a,c   Coates, Stephen ^b   Abrignani, Sergio ^b,d   Houghton, Michael ^b,e   Frey, Sharon E ^a   Belshe, Robert B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Novartis Vaccines and Diagnostics   (United States)

^c MICROBIOTIX INC   (United States)

^d Istituto Nazionale di Genetica Molecolare   (Italy)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY AFFINITY; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, NEUTRALIZING; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HIV; HUMANS; POLYSORBATES; SQUALENE; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 77955659499     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655902     Document Type: Article

References (15)

1. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994; 91: 1294-1298.
2. Lagging M, Meyer K, Owens RJ, et al. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus infectivity. J Virol 1998; 72:3539-3546.
3. Lagging M, Meyer K, Westin J, et al. Neutralization of pseudotyped VSV expressing HCV E1 or E2 by sera from patients. J Infect Dis 2002; 185:1165-1169.
4. Rothman AL, Morishima C, Bonkovsky HL, et al. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 2005; 41:617-625.
5. Meyer K, Basu A, Beyene A, et al. Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins display separable ligand sensitivity and increases pseudotype infectious titer. J Virol 2004; 78: 12838-12847.
6. Kanda T, Basu A, Steele R, et al. Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol 2006; 80:4633-4639.
7. Vermont CL, van Dijken HH, van Limpt CJ, et al. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 2002; 70:584-590.
8. Ray R, Khanna A, Lagging LM, et al. Peptide immunogen mimicry of putative E1 glycoprotein specific epitopes in hepatitis C virus. J Virol 1994; 68:4420-4426.
9. Meunier JC, Russell RS, Goossens V, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J Virol 2008; 82:966-973.
10. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992; 89:3468-3472.
11. Zhang P, Zhong L, Struble EB, et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 2009; 106:7537-7541.
12. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100:7271-7276.
13. Nie Y, Wang G, Shi X, et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 2004; 190:1119-1126.
14. Gottwein JM, Scheel TK, Jensen TB, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49:364-377.
15. von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132:667-678.